Introduction
Hematopoiesis is organized as a hierarchy of events controlled by both genetic commitment and external regulatory factors. Whether a hematopoietic stem cell self-renews or differentiates down the myeloid, lymphoid, or erythromegakaryocytic lineages, is determined by the pathways which regulate cell cycle status and gene expression profile. In acute myeloid leukemia, cells are arrested at an immature step of differentiation leading to an accumulation of granulocyte and monocyte precursors in the bone marrow and blood. All-trans retinoic acid (RA) induces differentiation of acute promyelocytic leukemia (APL) cells; this serves as an effective therapy and provides an opportunity to investigate the differentiation process 1 . We identified ASB2 (Ankyrin repeat-containing protein with a Suppressor of Cytokine signaling Box 2) as a gene activated during RA-induced-maturation of APL cells 2, 3 . ASB2 is also a target gene of the PML-RARα oncogenic transcription factor characteristic of APL 2, 4 . ASB2 expression inhibits growth and promotes commitment, recapitulating an early step critical for differentiation of myeloid leukemia cells 2 . ASB2 encodes a protein which harbors ankyrin repeats and a BC motif located within a SOCS box (Suppressor Of Cytokine Signaling). By interacting with the Elongin BC complex through its BC-box ASB2 can assemble with a Cullin5/Rbx module to reconstitute an E3 ubiquitin ligase complex that stimulates polyubiquitylation by the E2 ubiquitin-conjugating enzyme Ubc5 5, 6 . Within this complex, ASB2 is thought to target proteins for proteosomal degradation. However, ASB2 targets remained unknown.
Filamins are actin crosslinking protein found on stress fibers, in lamellae and in filopodiae. In addition to organizing F-actin, filamins anchor transmembrane and cytoplasmic signaling proteins involved in motility, adhesion and cell-shape modulation to the actin cytoskeleton, providing mechanical stability to the cell membrane and cell-cell or cellextracellular matrix connections [7] [8] [9] . Filamins also regulate the activity of several transcription factors 8, 10 . Filamins play essential roles throughout development and in the adult organism. Mutations in each of the human filamin genes have been linked to disease with phenotypes including embryonic lethality, defective neuronal migration, valvular dystrophy, congenital malformations and myofibrillar myopathy [11] [12] [13] . This diversity reveals that filamins perform a variety of essential functions particularly with respect to the skeletal and cardiovascular systems. Furthermore while it appears that complete loss of filamin A (FLNa) is usually lethal during embryonic development, the similarities between some phenotypes associated with FLNa and filamin B (FLNb) missense mutations and the overlap in their tissue distribution and binding partners suggests the potential for functional redundancy between these isoforms.
Here, we show that ASB2 ubiquitin ligase activity drives proteasome-mediated degradation of the actin-binding proteins FLNa and FLNb. This reveals a novel mechanism for controlling filamin levels through ubiquitin-mediated proteasomal degradation that has the potential to impact a wide range of filamin-dependent processes.
Materials and methods

Cell lines, culture conditions and measurements of differentiation
NB4 and PLB985 cells were used as described 2 . HeLa and HEK293T cells were grown in Dulbecco modified Eagle medium (DMEM) containing 4.5 g/l glucose (Invitrogen) and 5% fetal bovine serum (PAA laboratories). NIH3T3 cells were grown in DMEM containing 4.5 g/l glucose and 5 % new born calf serum (PAA laboratories). HT1080 cells were grown in DMEM containing 4.5 g/l glucose and 10 % fetal calf serum (Atlanta Biological). FLNa and FLNb double knockdown (HT1080 FLNabKD) were obtained transfecting HT1080 WT with shRNA against human FLNa (in pSM2c vector, Openbiosystem) and with shRNA against human FLNb (in pGIPZ vector, OpenBiosystem). After two days the transfected cells were selected using 4 µg/ml Puromycin and 1 mg/ml Hygromycin.
For cell spreading assays, 24 h after transfection NIH3T3 cells were trypsinized, washed in PBS and incubated in suspension for 1 hour at 37°C in serum free MEM containing 0.2 % bovine serum albumine (BSA). Cells were then plated on fibronectin-coated slides (BectonDickinson) for 45 min. Cells were considered spread if the cytoplasmic surface area was at least twice the nuclear surface area. HT1080 WT, HT1080 transfected with GFP-ASB2wt and HT1080 FLNab KD were trypsinized, re-plated on glass coverslips coated with 5 µg/ml Fibronectin (Sigma) and fixed with 4 % paraformaldehyde in PBS at the indicated time. Images were then taken in DIC using a 40x objective and cell area was measured using ImageJ software.
Plasmid constructs
Construction of an ASB2LA mutated plasmid was achieved using the QuikChange sitedirected mutagenesis kit (Stratagene). For this, the forward mutated oligonucleotide sequence was (mutated bases in bold face): 5'-CTCCAAGACCTGCGGCTCACCTTTGCCG-3'. Deletion of the SOCS box (amino acids 545 to 587) was generated by PCR amplification. ASB2 wild-type, LA and ΔSOCS fragments were subcloned into: (i) the pEGFP-C3 expression vector (Clontech), (ii) the pDsRed-monomerC1 expression vector (Clontech), (iii) pMTCB6 + -derived expression vectors to direct the expression of ASB2 fused to the FLAG epitope or to GFP at its amino terminus under the control of the zinc-inducible sheep metallothionein promoter 2 and (iv) the pBacPAK8 plasmid (Clontech). The pSG5FN-ASB2 expression vector was as described 5 . The Rbx2 coding sequence (RZPD) was subcloned into the pBacPAK8 vector. The human pcDNA3-FLNa-GFP 14 and pCl-puro-FLNb-GFP 15 expression constructs have been used previously. Human ubiquitin was subcloned into the pCMV3Tag7 vector (Stratagene) to direct the expression of ubiquitin fused to three Myc-tag at its amino terminus. Specific silencing of ASB2 was achieved by using a shRNA-expressing vector. Nucleotides 96-114 (sh#1) and 1370-1388 (sh#2) of the hASB2 coding sequence were chosen as target for shRNA. The siRNA sequences were used to construct 60-mer short hairpin (sh) RNA oligonucleotides, which were then synthesized (MWG), and ligated into the pSUPER.neo.gfp expression vector (Oligoengine) under the control of the H1 promoter. The following oligonucleotides were used (underlined, sense and antisense sequences; boldface, restriction enzyme sites; lightface italics, polIII termination signals; boldface italics, loop with linker):
sh#1: In vivo expression and protein extracts PLB985 cells were transfected using the nufleofector T solution and the O17 program, as recommended by the manufacturer (Amaxa). Cells were then cultured for 48 h prior to selection with 0.4 mg/ml G418 (Invitrogen). HeLa and NIH3T3 cells were transfected using Jet PEI (PolyPlus). Cells were washed twice in PBS 1X and resuspended in whole cell extract buffer (50 mM Tris-HCl, pH 7.9, 150 mM NaCl, 1 mM EDTA, 0.1 % NP40, 10 % glycerol, 1 mM dithiotreitol, 1 mM Na 3 VO 4 , 50 mM NaF, and 1 % protease inhibitor cocktail (P8340; Sigma). After two freeze-thaw cycles in liquid nitrogen, the resulting cell lysates were cleared by a 10 min 20,000 x g centrifugation at 4°C. HEK293T and HT1080 WT cells were transfected using lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Cells were lysed in RIPA buffer (50 mM Tris pH 7.2, 1% Triton X-100, 0.5% NaDeoxycolate, 0.1% SDS, 0.5 M NaCl, 10 mM MgCl 2 , Protease inhibitors cocktail), then cleared by a 10 min 15,000 x g centrifugation at 4°C.
Antibodies
The serum raised against ASB2 (1PNA) has been described previously 2 . Anti-Flag (2EL-1B11) was purchased from Euromedex. The mouse monoclonal antibody to polyubiquitinylated proteins (clone FK1), anti-FLNa (clones PM6/317 and TI10) and antinon-muscle myosin II heavy chain A were from Biomol International, Millipore and Covance, respectively. Polyclonal anti-FLNb was purchased from Chemicon, and anti-GFP was from Rockland. The anti-human FLNa antiserum which cross-reacts with mouse FLNa was raised in rabbits 16 .
Immunofluorescence
Cells were fixed in 4% paraformaldehyde in PBS supplemented with 15 mM sucrose and permeabilized with 0.1% Triton X-100. After blocking with 3% BSA in PBS, immunostaining of cells was performed using appropriate dilutions of antibody solutions as follows: antibodies to polyubiquitinylated proteins in 1:10000; human FLNa in 1:5000; mouse FLNa in 1:1000; non-muscle myosin IIA in 1:5000 and FLNb 1:200. F-actin was visualized with Alexa 568-or Rhodamine-phalloidin (Fisher) in 1:400. Secondary antibodies used were Alexa Fluor 633 coupled to goat anti-rabbit, goat anti-mouse and donkey anti-goat. Triple-immunofluorescence staining was performed using biotinylated goat anti-mouse IgG1 (Southern Biotechnology Associates) as the secondary antibody, cells were incubated for 20 min with Cy5-conjugated streptavidin (Jackson ImmunoResearch) and analyzed with a laser scanning confocal microscope (LSM 510 Zeiss). Preparations were mounted in mowiol (Calbiochem). When indicated, the numbers of cells were counted among a randomly selected pool of at least 100 cells expressing GFP-tagged proteins.
Quantification of FLNa expression by FACS
Cells were fixed in 3% paraformaldehyde in PBS and permeabilized in PMZ-T (PBS 1X, 0.2% BSA, 0.3% Triton X-100 and 50 mM NH 4 Cl). To assess FLNa levels, cells were incubated at room temperature for 1 h with 2 μg/ml mouse anti-FLNa (clone PM6/317) or anti-mouse IgG1 (BD Biosciences) as isotypic control, and then for 1 h with Alexa Fluor 647-conjugated anti-mouse antibodies (Invitrogen). Saturating concentrations of anti-FLNa antibodies were used. Samples were analyzed by flow cytometry using a FACScan.
In vitro ubiquitylation assays
Recombinant baculoviruses encoding ASB2LA, ASB2ΔSOCS and Rbx2 were generated with the BacPAK baculovirus expression system (Clontech). Baculoviruses encoding ASB2, only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From elongin B, elongin C, and cullin 5 were as described 5 . Expression of recombinant proteins in Sf21 insect cells were as previously described 5 . Cell extracts were immunoprecipitated with anti-Flag antibodies coupled to agarose beads (Sigma). After 3 washes with binding buffer and 2 washes with a buffer containing 40 mM Hepes-NaOH, pH 7.9, 60 mM potassium acetate, 1 mM MgCl 2 , 0.5 mM EDTA, 10% glycerol, 2 mM DTT, the beads were mixed with 133 nM of Uba1, 666 nM of UbcH5a, 333 μM ubiquitin (Boston Biochem) in a 20-μl reaction containing 4 mM Hepes NaOH, pH 7.9, 6 mM potassium acetate, 5 mM MgCl 2 , 1 mM DTT and 1.5 mM ATP. Reactions were incubated for 1h at 30°C. When indicated, 133 nM of APP-BP1/Uba3, 1 μM of Ubc12 and 25 µM of NEDD8 (Boston Biochem) were added. FLNa ubiquitylation assays were performed using immunopurified FLNa as a substrate in the reaction described above. Briefly, 150 μg of NB4 cell extracts were precleared by incubating 30 min in the presence of protein A-sepharose beads (GE Healthcare) at 4°C. Anti-FLNa (clone PM6/317) were added to the cell protein extract in a binding buffer adjusted to 20 mM Tris-HCl, pH 7.5, 150 mM NaCl and 0.1% NP40. After 2 h of incubation, immunocomplexes were recovered with protein A-sepharose. After 3 washes with binding buffer, proteins were eluted with 100 mM phosphate buffer, pH 12.5 and buffered to pH 8.5 for in vitro ubiquitylation assays. Reaction products were fractionated by SDS-PAGE and analyzed by immunoblotting with anti-FLNa and anti-ASB2 antibodies.
Results
ASB2 expression induces loss of FLNa
As a first step towards identifying ASB2 targets the subcellular localization of GFP-tagged ASB2 transiently expressed in HeLa cells was assessed by fluorescence microscopy. Ten hours after transfection ASB2 co-localized with F-actin in stress fibers, lamellae and filopodiae ( Figure 1A ). Similar observations were made using DsRed or Flag-tagged ASB2 (data not shown). Thus actin-associated proteins may be targets for ASB2-mediated degradation.
The sub-cellular localization of ASB2 is reminiscent of that of the actin-binding protein FLNa and 10 h after transfection of HeLa cells, endogenous FLNa co-localized with GFP-ASB2 in most cells ( Figure 1B ). However, 24 h post-transfection FLNa was undetectable in 59 ± 5% of GFP-ASB2 expressing cells ( Figure 1C ,D) suggesting that ASB2 may induce FLNa degradation. No loss of FLNa was observed in cells expressing GFP ( Figure 1C ). Calpain proteolysis of FLNa generates major N-and C-terminal fragments of ~190 and 100 kDa respectively 17 and this is implicated in FLNa-interacting protein (FILIP) -mediated FLNa degradation 18 . However, ASB2-induced loss of FLNa staining was observed using antibodies directed against either the N-or the C-terminus of FLNa suggesting that the absence of FLNa in ASB2 expressing cells is unlikely to be simply due to proteolytic cleavage of FLNa ( Figure 1C ). To confirm these results in another cell type and using biochemical assays, NIH3T3 cells were co-transfected with vectors expressing FLNa-GFP without or with GFP-ASB2. Twenty-four hours post transfection western blotting revealed that GFP-ASB2 expression resulted in a loss of FLNa-GFP ( Figure 1E ). Furthermore, no proteolytic fragments of FLNa-GFP were detected using antibodies directed against the Nterminus of FLNa or against the GFP. Although filamins act as actin crosslinkers, no drastic alteration of the actin cytoskeleton was observed in ASB2-expressing cells that have lost FLNa expression ( Figure 1F ). 
ASB2 ubiquitin ligase activity drives proteasome-mediated FLNa degradation
To determine if E3 ubiquitin ligase activity is required in ASB2-mediated FLNa degradation we generated ASB2 mutants defective in complex formation. Within the ASB2 SOCS (suppressor of cytokine signaling) box, the BC-box defines a binding site for the elongin BC complex whereas the Cul5 box determines the binding specificity for the cullin5/Rbx2 module 5, 6, 19 . A deletion mutant lacking the entire SOCS box (ASB2Δ) and a BC-box mutant (ASB2LA) were constructed (Figure 2A ). When expressed in Sf21 cells, immunopurified wild-type ASB2/elongin BC/cullin5/Rbx2 complex stimulated formation of ubiquitin conjugates by UbcH5a (Figure 2B ), as previously demonstrated for the ASB2/elongin BC/cullin5/Rbx1 complex 5 . However, despite comparable levels in the immunoprecipitations ASB2Δ and ASB2LA mutants failed to activate formation of polyubiquitin chains by the E2 enzyme ( Figure 2B ). The effect of these ASB2 mutants on FLNa levels was then tested. Twenty four hours after transfection of HeLa cells with GFP-ASB2LA or GFP-ASB2Δ levels of endogenous FLNa were unaffected while FLNa could not be detected in 55 ± 7 % of cells expressing GFP-ASB2wt ( Figure 2C ). This suggests that formation of an active E3 ubiquitin ligase complex is required for ASB2-mediated FLNa degradation. Loss of FLNa is mediated via the proteasome as treatment of HeLa cells with the proteasome inhibitor MG132 abolished ASB2-induced FLNa degradation ( Figure 2D ). To confirm these results, NIH3T3 cells were co-transfected with vectors expressing DsRed, DsRed-ASB2wt or DsRed-ASB2LA together with a FLNa-GFP expression vector. Twenty-four hours post transfection western blotting revealed that DsRed-ASB2wt expression resulted in a loss of FLNa-GFP ( Figure 2E ) while FLNa-GFP levels were not altered in cells expressing ASB2LA. Consistent with results in HeLa cells, proteasome inhibitors blocked FLNa-GFP degradation induced by DsRedASB2wt ( Figure 2E ).
To determine whether ASB2 can promote FLNa ubiquitylation, in vitro, substrate ubiquitylation assays were performed using purified FLNa. Even in the absence of specific substrate, the immunopurified wild-type ASB2/elongin BC/cullin5/Rbx2 complex stimulated formation of a ladder of ubiquitin conjugates, showing its intrinsic E3 ligase activity. Among the proteins that were polyubiquitylated in this reaction, ASB2 was found to be polyubiquitylated ( Figure 3 , lower panel, lanes 1 and 2). However, when FLNa was used as a substrate, ubiquitylation of FLNa by UbcH5a in the presence of the ASB2/Elongin BC/Cullin5/Rbx2 complex but not in the presence of ASB2Δ was observed ( Figure 3 , upper panel, lanes 2 and 3). Because NEDD8 modification of cullins activates the ubiquitin ligase activity of cullin-based E3 ligases [20] [21] [22] and because cullins are not neddylated following expression in insect cells, we wanted to determine whether ASB2-induced FLNa ubiquitylation was enhanced in the presence of the three components of the neddylation machinery, APP-BP1/Uba3, Ubc12 and NEDD8. As can be seen in Figure 3 , addition of the NEDD8 machinery stimulated ubiquitin conjugation significantly and resulted in increased conversion of FLNa into high molecular mass ubiquitin adducts (Figure 3, upper panel, lane  6) . Thus, ASB2 ubiquitin ligase activity drives ubiquitin-mediated proteasomal degradation of FLNa.
ASB2 expression induces proteasomal degradation of FLNb
To test whether ASB2 can also induce proteasomal degradation of the other widely expressed mammalian filamin, FLNb, NIH3T3 cells were transfected with vectors expressing GFPASB2wt or GFP-ASB2LA. Twenty hours post-transfection, FLNb was undetectable in 76 ± 5 % of GFP-ASB2wt expressing cells whereas no loss of FLNb was observed in cells expressing GFP-ASB2LA ( Figure 4A ). Furthermore, co-expression of GFP-ASB2wt, but not GFP-ASB2LA, resulted in the reduction of FLNb-GFP levels ( Figure 4B 
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FLNa, ASB2-induced loss of FLNb-GFP was prevented by proteasome inhibition ( Figure  4B ). Thus ASB2 targets both FLNa and FLNb for degradation. ASB2 does however show specificity as no degradation of another co-expressed actin-binding protein talin-GFP was observed ( Figure 4C ), nor were levels of the endogenous actin-binding proteins vinculin or non-muscle myosin heavy chain IIA affected (data not shown).
Knockdown of ASB2 in myeloid leukemia cells delays RA-induced differentiation and FLNa and b degradation
ASB2 was originally identified as an RA-induced gene in APL. We therefore investigated FLNa and b expression in promyelocytic NB4 and myeloblastic PLB985 cells. When cultured with RA these cells differentiated towards the granulocytic pathway ( Figure 5A ). Differentiation of PLB985 cells was slower and accordingly RA-induced ASB2 expression was delayed in these cells ( Figure 5B ). In both cell types ASB2 up-regulation correlated with loss of FLNa and b ( Figure 5B ) and FLNa was not or barely detectable in the differentiated cells ( Figure 5C ). To examine the role of ASB2 in filamin degradation during RA-induced differentiation of PLB985 cells, we established stable PLB985 cell lines expressing short hairpin RNAs directed against ASB2. In the absence of RA, these lines grow at the same rate as control cells (data not shown). ASB2 knockdown in PLB985 cells cultured in the presence of RA was obtained with sequence #1 (Figure 5D ). In these cells, FLNa and b degradation was delayed ( Figure 5D ). Cells expressing the shRNA #2, that did not affect ASB2 expression, showed a kinetic of filamin degradation identical to cells transfected with the empty vector ( Figure 5D ). Furthermore, ASB2 knockdown delayed the RA-induced growth arrest of PLB985 cells ( Figure 5E ) and reduced the number of cells expressing the differentiation marker CD11b ( Figure 5E ). However, the morphology and nitroblue tetrazolium reduction of control and ASB2 knockdown PLB985 cells was similar after 6 days of RA treatment (data not shown). Thus ASB2 knockdown delays growth arrest and differentiation of RA-treated PLB985 cells and ASB2 controls filamin degradation during RA-induced differentiation of myeloid leukemia cells.
ASB2 ubiquitin ligase activity drives FLNa and b degradation in myeloid leukemia cells
We next investigated PLB985 cells stably expressing empty vector, wild-type or mutant ASB2 under the control of the zinc-inducible metallothionein promoter. When zinc was added to the media, ASB2wt increased and endogenous FLNa and b decreased ( Figure 6A, lanes 1-4) . However, while equivalent amounts of ASB2wt, ASB2LA and ASB2Δ proteins were expressed, only wild-type ASB2 induced filamin degradation ( Figure 6A, lanes 5-8) . To visualize ASB2-induced FLNa degradation at the single cell level, GFP, GFP-ASB2wt or GFP-ASB2Δ was transiently expressed in PLB985 cells ( Figure 6B ). FLNa was undetectable in 90 % of the cells expressing GFP-ASB2wt but was unaffected by the ASB2 mutant. FLNa degradation was abolished by MG132-treatment of PLB985 cells ( Figure 6C ).
To additionally confirm these data and to provide more detailed information regarding the efficiency of ASB2-mediated FLNa down-regulation in myeloid leukemia cells, the expression of FLNa was determined together with the respective GFP expression by FACS analysis. Figure 6D shows the FLNa expression profile of PLB985/MT-GFP-ASB2 and PLB985/MT-GFP-ASB2Δ cells cultured with or without ZnSO 4 . The geometric mean FLNa expression in GFP-ASB2wt expressing cells was dramatically reduced to 18 ± 2 % of that seen in non-expressing cells while FLNa expression was not influenced by GFP-ASB2Δ, although similar quantities of ASB2 and ASB2Δ could be detected by flow cytometry ( Figure  6D ). Hence, ASB2 ubiquitin ligase activity mediates proteasomal degradation of FLNa in myeloid leukemia cells. 
ASB2 regulates integrin-mediated cell spreading through degradation of FLNs
To characterize further the effects of ASB2, NIH3T3 cells were transfected with GFP, GFPASB2wt, GFP-ASB2LA and GFP-ASB2Δ expression vectors, 24 hours later cells were trypsinized and then plated on fibronectin-coated slides. Expression of ASB2, but not ASB2 mutants, inhibited spreading of NIH3T3 cells 45 minutes after plating on fibronectin coated slides ( Figure 7A-B) . Similar results were obtained in HeLa cells (data not shown). To demonstrate the involvement of degradation of FLNs in ASB2-mediated effects on cell spreading, we tested stable FLNa and FLNb knockdown HT1080 cells ( Figure 7C ). When plated on fibronectin, the area of these cells was significantly decreased compared to that of control cells ( Figure 7D ). Similar observations were made in HT1080 cells expressing wildtype ASB2 ( Figure 7E ). Thus, ASB2 regulates integrin-mediated cell spreading through FLNa and b degradation.
Discussion
We have identified FLNa and b as the first ASB2 targets and shown that ASB2 triggers ubiquitylation and proteasome-mediated degradation of these proteins in physiologically relevant settings. To our knowledge, this is the first example of FLNa and b regulation via proteosomal degradation pathways and provides a mechanism by which ASB2 may modulate the many cytoskeletal and signaling pathways downstream of filamins. This further suggests that filamin degradation may play a role in ASB2-mediated hematopoietic cell differentiation.
As target cells for transformation in APL are likely to be a committed myeloid progenitor 23 , it is probable that genes involved in myeloid differentiation are repressed in APL cells and de novo expressed when these cells are induced to differentiate by RA. We identified ASB2 as a gene activated during RA-induced-maturation of APL cells 2, 3 . ASB2 is also a target gene of the PML-RARα oncogenic transcription factor characteristic of APL and ASB2 expression inhibits growth and promotes commitment, recapitulating an early step critical for differentiation of myeloid leukemia cells 2 . Although ASB2 is not sufficient on it's own to induce terminal differentiation of myeloid leukemia cells 2 , we show that knockdown of endogenous myeloid leukemia cell ASB2 delays RA-induced differentiation. Thus, ASB2 is a gene involved in cell differentiation whose function may be altered in APL 2, 3 . ASB2 forms part of an E3 ubiquitin ligase complex 5, 6 and was thought to target proteins for proteosomal degradation. Identification of ASB2 targets and verification that they are indeed targeted for degradation is therefore key to understanding ASB2 function. Here we show that ASB2 targets FLNa and b to proteasomal degradation and that knockdown of endogenous ASB2 in myeloid leukemia cells delays FLNa and b degradation. These suggest that ASB2-induced FLNa and b degradation may regulate signaling pathways that are disrupted during transformation by PML-RARα. Indeed, alteration of receptors and subsequent signaling plays a critical role in the pathogenesis of acute myeloid leukemia 24, 25 . Accordingly, a number of signal transduction pathways are known to be activated during induced-maturation of myeloid leukemia cells 25, 26 . Which pathways downstream of filamin are perturbed, and the mechanisms by which ASB2-induced loss of filamin impacts cell differentiation, are the subject of ongoing investigations.
We note that we cannot exclude the possibility that other ASB2 targets are also important during ASB2-induced differentiation, although we did not detect effects on talin, vinculin, or myosin heavy chain, and the cytoskeletal organization of ASB2-expressing cells was not grossly perturbed, suggesting that ASB2 does not induce widespread degradation of cytoskeletal proteins. It will nonetheless be important to identify the sites of ubiquitinylation only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From within FLNa and FLNb and so to generate degradation resistant filamins. However, the number of lysines in these large proteins (156 in FLNa and 173 in FLNb) combined with the possibility that multiple lysines may be modified makes this a major challenge to be addressed in future studies.
As wild-type ASB2 transiently co-localized with F-actin, ASB2 is likely to induce degradation of filamins that are associated with F-actin. When filamin is completely degraded ASB2 is diffuse throughout the cytoplasm suggesting that the colocalization of ASB2 with Factin may be due to ASB2 association with FLNa and/or b. Accordingly, ASB2 mutants that are unable to stimulate filamin degradation accumulate on stress fibers. Surprisingly, despite the proposed roles for filamins in organization of F-actin no drastic alteration of the actin cytoskeleton was observed in ASB2 transfected cells. However, expression of ASB2, but not ASB2 mutants, did inhibit spreading of NIH3T3, HeLa and HT1080 cells on fibronectin coated slides. Thus, ASB2 regulates integrin-mediated cell spreading. Furthermore, knockdown of FLNa and FLNb also inhibited cell spreading on fibronectin demonstrating that the cell spreading defect of ASB2-expressing cells is due to its effect on FLNa and/or b degradation. Certain FLN-ligand interactions are regulated by receptor occupancy, phosphorylation, alternative splicing and auto-inhibition 14,15,27-29 but ASB2 represents a novel mechanism for controlling both FLNa and b levels that has the potential to impact a wide range of filamin-dependent processes. Indeed, FLNa acts as a scaffold for signalling molecules involved in actin remodelling including GTPases such as Rac1, Cdc42, RhoA and RalA 30, 31 , Rho GEFs (guanine nucleotide-exchange factors) such as Trio 32 and Lbc 33 , Rho GAPs (GTPase-activating proteins) such as FilGAP and p190RhoGAP 34, 35 , p21-activated kinase 1 (Pak1) 36 and the Rho kinase (ROCK) 37 . Through FLNa degradation, ASB2 may regulate these pathways thereby leading to the regulation of actin remodelling.
The ASB2 gene was identified as an RA-induced gene in APL cells 2, 3 . However, ASB2 is specifically expressed in immature normal hematopoietic cells and this expression is lost in peripheral blood leukocytes 2 so ASB2 is likely to be relevant during early hematopoiesis. The absence of ASB2 expression in mature leukocytes is consistent with the expression of FLNs in these cells 38 . Cytoskeletal reorganization and response to mechanical stimuli is involved in the control of cell growth, differentiation and stem cell lineage switching 39 . Furthermore, integrin adhesion molecules, which bind directly to filamins, play a major role in anchoring hematopoietic stem cells to the hematopoietic niche during development 40 and following transplantation in mice 41, 42 . In this regard, it is noteworthy that ASB2 can regulate integrin-mediated spreading and it is tempting to speculate that by targeting FLNa and/or b to proteasomal degradation, ASB2 may modulate bone marrow homing and/or engraftment of hematopoietic stem cells. In summary, our identification of filamins as targets for ASB2-induced degradation should stimulate future detailed mechanistic studies of the roles of filamins as actin crosslinkers or signaling scaffolds during hematopoesis and reinforces the view that targeting proteins to proteasomal degradation may be an important step in the control of hematopoiesis 43 . 
